Sub menu

 
 

ZEPOSIA (Celgene Pty Ltd)

Product name
ZEPOSIA
Sponsor
Celgene Pty Ltd
Date registered
Evaluation commenced
Decision date
Approval time
196 (255 working days)
Active ingredients
ozanimod hydrochloride
Registration type
EOI
Indication
Ulcerative Colitis

ZEPOSIA (capsule) is now also indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological therapy.

Help us improve the Therapeutic Goods Administration site